Cell nucleus

Small Molecule Shows Early-Stage Promise for Repairing Myelin Sheath Damage

Retrieved on:

Donnerstag, Mai 2, 2024

CINCINNATI, May 2, 2024 /PRNewswire/ -- When treated with a novel protein function inhibitor called ESI1, mice that mimic the symptoms of multiple sclerosis (MS) and lab-prepared human brain cells both demonstrated the ability to regenerate vital myelin coatings that protect healthy axon function.

Key Points:

When the protective myelin gets damaged, be it by disease or the wear and tear of age, nerve signaling gets disrupted.
Pinning down the genetic changes and signals involved in the repair silencing process and finding a small molecule compound that can reverse the silencing was a complex undertaking.
In both aging mice and mice mimicking MS, the ESI1 treatment prompted myelin sheath production and improved lost neurological function.
When the organoids were exposed to ESI1, the treatment extended the myelin sheath of myelinating cells, the study reports.

Mblue Labs Discovers Anti-Aging Power In Methylene Blue, Launches Bluelene Face&Neck Remodel Mask

Retrieved on:

Mittwoch, März 13, 2024

Bethesda, Maryland--(Newsfile Corp. - March 13, 2024) - Mblue Labs proudly announces the debut of the Face & Neck Remodel Mask, a groundbreaking addition to their renowned skincare brand, Bluelene.

Key Points:

Bethesda, Maryland--(Newsfile Corp. - March 13, 2024) - Mblue Labs proudly announces the debut of the Face & Neck Remodel Mask, a groundbreaking addition to their renowned skincare brand, Bluelene.
Mblue Labs, a woman and minority-owned business, is dedicated to advancing skincare science, and this latest product embodies their commitment to unparalleled innovation.
Methylene Blue penetrates skin cells at the mitochondrial level, creating cell health and proliferation.
To view an enhanced version of this graphic, please visit:
The Face & Neck Remodel Mask features a powerful blend of the latest age-reversal ingredients, including Methylene Blue, Growth Factors, Advanced Peptides, and Niacinamide.

DNA Contamination of COVID Vaccines Explored in Journal of American Physicians and Surgeons

Retrieved on:

Montag, Dezember 11, 2023

“The plasmid DNA contamination theory is not a sensational internet rumor, but a reality-based hypothesis prompted by standard laboratory research performed by professional researchers,” she writes.

Key Points:

“The plasmid DNA contamination theory is not a sensational internet rumor, but a reality-based hypothesis prompted by standard laboratory research performed by professional researchers,” she writes.
The Pfizer mRNA vaccine used in clinical trials employed a polymerase chain reaction (PCR) process to make the DNA that coded for the mRNA (Process 1).
But scaling up production to make millions of doses used plasmids, small circular pieces of DNA in bacterial cells (Process 2).
The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS) , a national organization representing physicians in all specialties since 1943.

SOLA Biosciences Presents Preclinical Proof-of-Concept Data for SOL-257, a Gene Therapy Targeting Misfolded TDP-43 in ALS, at Neuroscience 2023 and ALS One Symposium

Retrieved on:

Donnerstag, November 9, 2023

Health, Neurology, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, AAV, Hope, Toxicity, HSP70, Cytoplasm, TAR, Neuroscience, Cell nucleus, RNA, Pharmaceutical industry, ALS

As a pioneer in innovative chaperone technology, SOLA Biosciences Inc. will present its compelling preclinical proof-of-concept data for SOL-257, a targeted gene therapy for misfolded TDP-43 in Amyotrophic Lateral Sclerosis (ALS), at Neuroscience 2023 in Washington, D.C. on November 15 and the ALS One Symposium on November 17.

Key Points:

As a pioneer in innovative chaperone technology, SOLA Biosciences Inc. will present its compelling preclinical proof-of-concept data for SOL-257, a targeted gene therapy for misfolded TDP-43 in Amyotrophic Lateral Sclerosis (ALS), at Neuroscience 2023 in Washington, D.C. on November 15 and the ALS One Symposium on November 17.
In vivo proof-of-concept studies have showcased the effectiveness of SOL-257 gene therapy in alleviating TDP-43-related toxicity in both the TDP-43-based mouse model and the C9orf72-based ALS mouse model.
“Our findings underscore SOL-257 as a highly promising translational therapy for ALS,” stated Dr. Akinori Hishiya, Chief Scientific Officer at SOLA.
Committed to excellence, we are advancing this promising therapy, striving to bring hope to the ALS community.”

The first dog-fox hybrid points to the growing risk to wild animals of domestic species

Retrieved on:

Donnerstag, September 28, 2023

However, the discovery of a dog-fox hybrid in Brazil suggests that The Fox and the Hound might sometimes be a little more Lady and the Tramp.

Key Points:

However, the discovery of a dog-fox hybrid in Brazil suggests that The Fox and the Hound might sometimes be a little more Lady and the Tramp.
Genetic testing revealed that she was a hybrid between a female pampas fox (Lycalopex gymnocercus) and a male domestic dog (Canis lupus familiaris).
Genetic analysis revealed she had a total of 76 chromosomes, compared to the 78 chromosomes of the domestic dog and 74 of the pampas fox.

What is a hybrid?

Differences in the number of chromosomes (the structure in which DNA is packaged within the cell nucleus) often make species genetically incompatible with each other.
For example, dogs (Canis lupus familiaris) and grey wolves (Canis lupus) only diverged between 11,000 and 35,000 years ago.
Even if differences in chromosome numbers and behaviour don’t prevent two species from producing young, it may make the hybrid infertile.

How common are hybrids?

Research suggests that approximately 25% of plant and 10% of animal species have been affected by interbreeding in the wild.
In Poland, a 2018 study found high numbers of free-living wild boars had domestic genes, for example.
Hybrid offspring are not always infertile, and some people are concerned about how this affects the long-term survival and purity of individual species.

Why are hybrids controversial?

Long term, hybrids can lead to the development of entirely new species.
Physical abnormalities are common in hybrids including changes to skull, dental and horn structures, as seen in hybrid wildebeest.
The Scottish wildcat wild population, for instance, is now almost entirely made up of wildcat-domestic cat hybrids.

What does the dog-fox hybrid tell us?

The dog-pampas fox hybrid strongly suggests that contact between wild and domestic species is increasing, possibly because of human settlements encroaching on wild habitats.
The dogxim might well be a warning of the destructive impact humans and domesticated animals are having on biodiversity.
It is important to note that the pampas fox species is very different to the red fox (Vulpes vulpes).

Stowers scientists find evidence of unintended impacts from anti-cancer drugs

Retrieved on:

Mittwoch, August 23, 2023

KANSAS CITY, Mo., Aug. 23, 2023 /PRNewswire/ -- With around 90% of drugs failing to make it to market, the potential for improving efficiency within the drug development industry is clear. Drugs designed to combat cancers suffer similar rates of failure for many reasons. Now, researchers have revealed one reason why certain anti-cancer compounds can cause unexpected side effects. This research could help guide an understanding of why some drugs show more promise than others, providing a new tool that can be used to identify those drugs and drug candidates.

Key Points:

This research could help guide an understanding of why some drugs show more promise than others, providing a new tool that can be used to identify those drugs and drug candidates.
Thus, the team found a way to capitalize on this variation and asked how chemotherapy drugs impact the nucleolus, causing nucleolar stress.
"In this study, we not only evaluated how anti-cancer drugs alter the appearance of nucleoli, but also identified categories of drugs that cause distinct nucleolar shapes," said Gerton.
Drugs often fail in clinical trials due to excessive and unintended toxicity that can be caused by their off-target effects.

Kanazawa University research: Brain cancer linked to nuclear pore alterations

Retrieved on:

Dienstag, August 22, 2023

KANAZAWA, Japan, Aug. 22, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cell Reports how alterations in the nuclear pores lead to the degradation of anti-tumor proteins.

Key Points:

KANAZAWA, Japan, Aug. 22, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cell Reports how alterations in the nuclear pores lead to the degradation of anti-tumor proteins.
Several types of cancer are believed to be linked to alterations of macromolecular structures known as nuclear pore complexes (NPCs).
Whether NPC alterations play a role in glioblastoma, the most common type of cancer originating in the brain, is unclear at the moment.
Mitsutoshi Nakada and Richard Wong and colleagues first checked whether any nuclear pore complex proteins were amplified ('overexpressed') in glioblastoma.

Kanazawa University research: Brain cancer linked to nuclear pore alterations

Retrieved on:

Dienstag, August 22, 2023

KANAZAWA, Japan, Aug. 22, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cell Reports how alterations in the nuclear pores lead to the degradation of anti-tumor proteins.

Key Points:

KANAZAWA, Japan, Aug. 22, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cell Reports how alterations in the nuclear pores lead to the degradation of anti-tumor proteins.
Several types of cancer are believed to be linked to alterations of macromolecular structures known as nuclear pore complexes (NPCs).
Whether NPC alterations play a role in glioblastoma, the most common type of cancer originating in the brain, is unclear at the moment.
Mitsutoshi Nakada and Richard Wong and colleagues first checked whether any nuclear pore complex proteins were amplified ('overexpressed') in glioblastoma.

Dr. Kieran Murphy Presents Results of Clinical Trial Demonstrating Positive Effect Protecting DNA From Radiation Exposure

Retrieved on:

Samstag, Mai 27, 2023

Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.

Key Points:

Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.
During these high-intensity image-guided procedures, physicians were administered the antioxidant complex as two capsules, one hour prior to exposure.
Dr. Murphy's team has successfully demonstrated the protection of mitochondrial DNA from radiation in these subjects, marking a significant milestone in medical literature.
Considering that mitochondrial DNA is inherited maternally and is 13 times more vulnerable to radiation than nuclear DNA, this achievement holds tremendous promise.

Dr. Kieran Murphy Presents Results of Clinical Trial Demonstrating Positive Effect Protecting DNA From Radiation Exposure

Retrieved on:

Samstag, Mai 27, 2023

Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.

Key Points:

Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.
During these high-intensity image-guided procedures, physicians were administered the antioxidant complex as two capsules, one hour prior to exposure.
Dr. Murphy's team has successfully demonstrated the protection of mitochondrial DNA from radiation in these subjects, marking a significant milestone in medical literature.
Considering that mitochondrial DNA is inherited maternally and is 13 times more vulnerable to radiation than nuclear DNA, this achievement holds tremendous promise.